⌘K
t
EKF Diagnostics Holdings plc cancelled 13,710,698 Ordinary Shares, previously acquired under its share buyback programme, with effect from 02 December 2025. Following this cancellation, the Company's total issued share capital consists of 435,383,092 Ordinary Shares, each with one voting right, and EKF will not hold any Ordinary Shares in treasury.
| Date | 8 Dec 2025 |
| Time | 07:00:03 |
| Category | Capital structure |
| ID | 5220K |
EKF Diagnostics Holdings plc
("EKF" or the "Company")
Cancellation of Treasury Shares & TVR
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, refers to its announcement dated 24 November 2025, in connection with the Company's share buyback programme totalling 13,710,698 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares"). The Company confirms that these Ordinary Shares, have now been cancelled with effect from 02 December 2025, in accordance with the provisions of section 729 of the Companies Act 2006 (the "Cancellation").
Further details in connection with the Cancellation can be found below:
|
Date of Cancellation |
02 December 2025 |
|
Number of Ordinary Shares cancelled pursuant to the share buyback programme |
13,710,698 |
|
Total number of Ordinary Shares cancelled |
13,710,698 |
Following Cancellation, the Company's total issued share capital consists of 435,383,092 Ordinary Shares with one voting right per share. The Company will not hold any Ordinary Shares in treasury.
Therefore, the total number of voting rights in the Company will be of 435,383,092.
The above figure of 435,383,092 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.
|
EKF Diagnostics Holdings plc |
|||
|
Julian Baines, Executive Chair |
Via Walbrook PR |
||
|
Gavin Jones, Chief Executive Officer |
|
||
|
|
Tel: +44 (0)20 7496 3000 |
||
|
Singer Capital Markets (Nominated Adviser & Broker) |
|
||
|
Phil Davies / Oliver Platts |
|
||
|
|
|
||
|
Walbrook PR Limited |
Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com |
||
|
Paul McManus / Alice Woodings |
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 |
||
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is an AIM-listed global diagnostics business focussed on:
· Point-of-Care analysers in the key areas of Hematology and Diabetes.
· Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic food and industrial applications.
EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.